Literature DB >> 28222998

Dynamics of APC recruitment at the site of injection following injection of vaccine adjuvants.

Susan van Aalst1, Irene Stephanie Ludwig2, Peter Johannes Sylvester van Kooten3, Ruurd van der Zee4, Willem van Eden5, Femke Broere6.   

Abstract

Vaccines often contain adjuvants to strengthen the response to the vaccine antigen. However, their modes of action at the site of injection (SOI) are poorly understood. Therefore, we assessed the local effects of adjuvant on the innate immune system in mice. We investigated the safe, widely used adjuvants MF59 and aluminum hydroxide (alum), as well as trehalose-6,6'-dibehenate (TDB), Complete Freund's Adjuvant (CFA) and the Toll-Like-Receptor-ligands lipopolysaccharide (LPS) and Pam3CysSerLys4 (Pam3CSK4). We assessed muscle immune cell infiltration after adjuvant injection and observed 16h post immunization (hpi) an increased influx with CFA, MF59 and TDB, but not with alum, LPS or Pam3CSK4. An elevated influx with the latter three became visible only 72hpi. Contribution of granulocytes, macrophages and dendritic cells to the influx differed per adjuvant and in time. Adjuvants generally induced a local pro-inflammatory micro-milieu that was transient except for CFA and TDB. The gene expression of CXCL-1, CCL-2 and CCL-5, involved in recruitment of immune cells, varied per adjuvant and corresponded grossly with the observed influx of granulocytes and monocytes/macrophages. Muscles injected with CFA or MF59 (when co-injected with peptide) resulted in APC ex vivo capable to induce proliferation of peptide-specific T-cells. By adding in vitro an excess of peptide to the APC/T cell co-cultures, we observed an adjuvant-enhanced co-stimulation or antigen presentation by APC after CFA- but not MF59-injection. After TDB-injection this effect was observed only at 72hpi, but not 24hpi. Thus the cellular influx profile and the local cytokine and chemokine micro-milieu in the muscle were strongly influenced by the type of adjuvant. Additionally, the capacity of muscle APC to load and present antigen was affected by the adjuvant. These findings may assist the development of novel adjuvanted vaccines in a more rational manner.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APC; Innate immunity; Mechanism of action; Muscle immunity; Site of injection; Vaccine adjuvant

Mesh:

Substances:

Year:  2017        PMID: 28222998     DOI: 10.1016/j.vaccine.2017.02.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

2.  Combining activatable nanodelivery with immunotherapy in a murine breast cancer model.

Authors:  Azadeh Kheirolomoom; Matthew T Silvestrini; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Spencer K Tumbale; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2019-04-09       Impact factor: 9.776

3.  The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Authors:  Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman
Journal:  Vaccine       Date:  2018-06-14       Impact factor: 3.641

4.  Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination.

Authors:  Devin G Fisher; Gaia M Coppock; Carolina B López
Journal:  Vaccine       Date:  2018-05-31       Impact factor: 3.641

5.  Bystander activation of irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence of adjuvant.

Authors:  Susan van Aalst; Irene S Ludwig; Ruurd van der Zee; Willem van Eden; Femke Broere
Journal:  PLoS One       Date:  2017-05-10       Impact factor: 3.240

Review 6.  Designing spatial and temporal control of vaccine responses.

Authors:  Gillie A Roth; Vittoria C T M Picece; Ben S Ou; Wei Luo; Bali Pulendran; Eric A Appel
Journal:  Nat Rev Mater       Date:  2021-09-28       Impact factor: 76.679

7.  Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium.

Authors:  January Weiner; David J M Lewis; Jeroen Maertzdorf; Hans-Joachim Mollenkopf; Caroline Bodinham; Kat Pizzoferro; Catherine Linley; Aldona Greenwood; Alberto Mantovani; Barbara Bottazzi; Philippe Denoel; Geert Leroux-Roels; Kent E Kester; Ingileif Jonsdottir; Robert van den Berg; Stefan H E Kaufmann; Giuseppe Del Giudice
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

8.  Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice.

Authors:  Yu Zheng; Lijun Bian; Huiting Zhao; Yulan Liu; Jingcai Lu; Dawei Liu; Ke Zhang; Yueshuang Song; Yusi Luo; Chunlai Jiang; Yan Chen; Yong Zhang; Wei Kong
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.